[go: up one dir, main page]

AR103990A1 - Ureas cíclicas como inhibidoras de rock - Google Patents

Ureas cíclicas como inhibidoras de rock

Info

Publication number
AR103990A1
AR103990A1 ARP160100053A ARP160100053A AR103990A1 AR 103990 A1 AR103990 A1 AR 103990A1 AR P160100053 A ARP160100053 A AR P160100053A AR P160100053 A ARP160100053 A AR P160100053A AR 103990 A1 AR103990 A1 AR 103990A1
Authority
AR
Argentina
Prior art keywords
substituted
independently selected
nrara
chrd
rnrac
Prior art date
Application number
ARP160100053A
Other languages
English (en)
Inventor
S Bhide Rajeev
Savanor Maddu Rao Prasanna
Chinnakotti Sankarankovil Kumaresan
Patil Sharanabasappa
Dnyanoba Yadav Navnath
Shrikrishna Bodas Mandar
W Glunz Peter
F Sitkoff Doree
Shetty Jeevanprakash
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR103990A1 publication Critical patent/AR103990A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Estos compuestos son inhibidores de ROCK selectivos. También se refiere a composiciones farmacéuticas que comprenden estos compuestos y a métodos para tratar trastornos cardiovasculares, trastornos relacionados con el músculo liso, trastornos oncológicos, trastornos neuropatológicos, trastornos autoinmunitarios, trastornos fibróticos y/o trastornos inflamatorios mediante su uso. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) o un enantiómero, diastereómero, estereoisómero, tautómero, sal de aquel aceptable desde el punto de vista farmacéutico, en donde - - - es un enlace opcional; el anillo A se selecciona independientemente de los compuestos del grupo de fórmulas (2); J¹, J², J³ y J⁴ se seleccionan independientemente de N y CR³, siempre que no más de dos de J¹, J², J³ y J⁴ sean N; K se selecciona independientemente de N y CR¹; R¹ se selecciona independientemente de H, F, Cl, Br, OH, CN, NRᵃRᵃ, -OC₁₋₄ alquilo sustituido con 0 - 3 Rᵉ y C₁₋₄ alquilo sustituido con 0 - 3 Rᵉ; R² se selecciona independientemente de H, (CH₂)ʳORᵇ, (CH₂)ʳS(O)ₚRᶜ, (CH₂)ʳC(=O)Rᵇ, (CH₂)ʳNRᵃRᵃ, (CH₂)ʳCN, (CH₂)ʳC(=O)NRᵃRᵃ, (CH₂)ʳNRᵃC(=O)Rᵇ, (CH₂)ʳNRᵃC(=O)NRᵃRᵃ, (CH₂)ʳNRᵃC(=O)ORᵇ, (CH₂)ʳOC(=O)NRᵃRᵃ, (CH₂)ʳC(=O)ORᵇ, (CH₂)ʳS(O)ₚNRᵃRᵃ, (CH₂)ʳNRᵃS(O)ₚNRᵃRᵃ, (CH₂)ʳNRᵃS(O)ₚRᶜ, (CH₂)ʳC₃₋₆ carbociclilo sustituido con 0 - 3 Rᵉ y (CH₂)ʳheterociclilo sustituido con 0 - 3 Rᵉ; R³ se selecciona independientemente de H, F, Cl, Br, CN, C₁₋₄ alquilo sustituido con 0 - 3 Rᵉ, (CH₂)ʳORᵇ, (CH₂)ʳS(O)ₚRᶜ, (CH₂)ʳC(=O)Rᵇ, (CH₂)ʳNRᵃRᵃ, (CH₂)ʳC(=O)NRᵃRᵃ, (CH₂)ʳC(=O)(CH₂)ʳNRᵃRᵃ, (CH₂)ʳCN, (CH₂)ʳNRᵃC(=O)Rᵇ, (CH₂)ʳNRᵃC(=O)ORᵇ, (CH₂)ʳOC(=O)NRᵃRᵃ, (CH₂)ʳNRᵃC(=O)NRᵃRᵃ, (CH₂)ʳC(=O)ORᵇ, (CH₂)ʳS(O)ₚNRᵃRᵃ, (CH₂)ʳNRᵃS(O)ₚNRᵃRᵃ, (CH₂)ʳNRᵃS(O)ₚRᶜ, (CH₂)ʳC₃₋₆ carbociclilo sustituido con 0 - 3 Rᵉ y (CH₂)ʳheterociclilo sustituido con 0 - 3 Rᵉ; R⁴ se selecciona independientemente de H, F, Cl, Br, OH, CN, OC₁₋₄ alquilo sustituido con 0 - 3 Rᵉ, NRᵃRᵃ y C₁₋₄ alquilo sustituido con 0 - 3 Rᵉ; R⁵ se selecciona independientemente de H, =O, C₁₋₄ alquilo sustituido con 0 - 4 Rᵉ, (CH₂)ʳORᵇ, (CH₂)ʳS(O)ₚRᶜ, (CH₂)ʳC(=O)Rᵇ, (CH₂)ʳNRᵃRᵃ, (CH₂)ʳCN, (CH₂)ʳC(=O)NRᵃRᵃ, (CH₂)ʳNRᵃC(=O)Rᵇ, (CH₂)ʳNRᵃC(=O)NRᵃRᵃ, (CH₂)ʳNRᵃC(=O)ORᵇ, (CH₂)ʳOC(=O)NRᵃRᵃ, (CH₂)ʳC(=O)ORᵇ, (CH₂)ʳS(O)ₚNRᵃRᵃ, (CH₂)ʳNRᵃS(O)ₚNRᵃRᵃ, (CH₂)ʳNRᵃS(O)ₚRᶜ, (CH₂)ʳC₃₋₆ carbociclilo sustituido con 0 - 3 Rᵉ y (CH₂)ʳheterociclilo sustituido con 0 - 3 Rᵉ; R⁶ y R⁷ se seleccionan independientemente de H, C₁₋₄ alquilo sustituido con 0 - 4 Rᵉ, (CH₂)ʳORᵇ, (CH₂)ʳS(O)ₚRᶜ, (CH₂)ʳC(=O)Rᵇ, (CH₂)ʳNRᵃRᵃ, (CH₂)ʳC(=O)NRᵃRᵃ, (CH₂)ʳC(O)(CH₂)ʳNRᵃRᵃ, (CH₂)ʳNRᵃC(=O)Rᵇ, (CH₂)ʳNRᵃC(=O)ORᵇ, (CH₂)ʳOC(=O)NRᵃRᵃ, (CH₂)ʳNRᵃC(=O)NRᵃRᵃ, (CH₂)ʳC(=O)ORᵇ, (CH₂)ʳS(O)ₚNRᵃRᵃ, (CH₂)ʳNRᵃS(O)ₚRᶜ, (CH₂)ʳC₃₋₆ carbociclilo sustituido con 0 - 3 Rᵉ y (CH₂)ʳheterociclilo sustituido con 0 - 3 Rᵉ; R⁸ se selecciona independientemente de C₃₋₆ cicloalquilo, heterociclilo, arilo y heteroarilo cada uno sustituido con 0 - 5 R⁹; R⁹ se selecciona independientemente de F, Cl, Br, C₁₋₄ alquilo, C₂₋₄ alquenilo, C₂₋₄ alquinilo, nitro, -(CHRᵈ)ʳS(O)ₚRᶜ, -(CHRᵈ)ʳS(O)ₚNRᵃRᵃ, -(CHRᵈ)ʳNRᵃS(O)ₚRᶜ, -(CHRᵈ)ʳORᵇ, -(CHRᵈ)ʳCN, -(CHRᵈ)ʳNRᵃRᵃ, -(CHRᵈ)ʳNRᵃC(=O)Rᵇ, -(CHRᵈ)ʳNRᵃC(=O)NRᵃRᵃ, -(CHRᵈ)ʳC(=O)ORᵇ, -(CHRᵈ)ʳC(=O)Rᵇ, -(CHRᵈ)ʳOC(=O)Rᵇ, -(CHRᵈ)ʳ-cicloalquilo, -(CHRᵈ)ʳ-heterociclilo, -(CHRᵈ)ʳ-arilo y -(CHRᵈ)ʳ-heteroarilo, en donde el alquilo, cicloalquilo, heterociclilo, arilo o heteroarilo se sustituye con 0 - 4 Rᵉ; Rᵃ, en cada caso, se selecciona independientemente de H, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, (CH₂)ʳC₃₋₁₀ carbociclilo sustituido con 0 - 5 Rᵉ y (CH₂)ʳheterociclilo sustituido con 0 - 5 Rᵉ; o Rᵃ y Rᵃ, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico sustituido con 0 - 5 Rᵉ; Rᵇ, en cada caso, se selecciona independientemente de H, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, (CH₂)ʳC₃₋₁₀ carbociclilo sustituido con 0 - 5 Rᵉ y (CH₂)ʳheterociclilo sustituido con 0 - 5 Rᵉ; Rᶜ, en cada caso, se selecciona independientemente de C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, C₃₋₆ carbociclilo y heterociclilo; Rᵈ, en cada caso, se selecciona independientemente de H y C₁₋₄ alquilo sustituido con 0 - 5 Rᵉ; Rᵉ, en cada caso, se selecciona independientemente de C₁₋₆ alquilo sustituido con 0 - 5 Rᶠ, C₂₋₆ alquenilo, C₂₋₆ alquinilo, (CH₂)ʳC₃₋₆ cicloalquilo, (CH₂)ʳC₄₋₆ heterociclilo, (CH₂)ʳarilo, (CH₂)ʳheteroarilo, F, Cl, Br, CN, NO₂, =O, CO₂H, (CH₂)ʳORᶠ, S(O)ₚRᶠ, C(=O)NRᶠRᶠ, NRᶠC(=O)Rᵈ, S(O)ₚNRᶠRᶠ, NRᶠS(O)ₚRᵈ, NRᶠC(=O)ORᵈ, OC(=O)NRᶠRᶠ y (CH₂)ʳNRᶠRᶠ; Rᶠ, en cada caso, se selecciona independientemente de H, F, Cl, Br, CN, OH, C₁₋₅ alquilo, C₃₋₆ cicloalquilo y fenilo, o Rᶠ y Rᶠ, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico opcionalmente sustituido con C₁₋₄ alquilo; n se selecciona independientemente de 1, 2 y 3; p, en cada caso, se selecciona independientemente de 0, 1 y 2; r, en cada caso, se selecciona independientemente de 0, 1, 2, 3 y 4; y siempre que (i) R⁹ no sea una piperazina sustituida; (ii) cuando n sea 3, R⁸ no sea un resto de fórmula (3); y (iii) cuando A sea el compuesto de fórmula (4), R² no sea C(=O)NRᵃRᵃ, NRᵃC(O)Rᵇ y -NRᵃC(=O)NRᵃRᵃ.
ARP160100053A 2015-01-09 2016-01-08 Ureas cíclicas como inhibidoras de rock AR103990A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562101434P 2015-01-09 2015-01-09

Publications (1)

Publication Number Publication Date
AR103990A1 true AR103990A1 (es) 2017-06-21

Family

ID=55310909

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100053A AR103990A1 (es) 2015-01-09 2016-01-08 Ureas cíclicas como inhibidoras de rock

Country Status (8)

Country Link
US (1) US10123993B2 (es)
EP (1) EP3242873B1 (es)
JP (1) JP6779214B2 (es)
CN (1) CN107406426B (es)
AR (1) AR103990A1 (es)
ES (1) ES2815681T3 (es)
TW (1) TW201630899A (es)
WO (1) WO2016112236A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406426B (zh) 2015-01-09 2020-11-20 百时美施贵宝公司 作为rock抑制剂的环状脲类
EP3268360B1 (en) * 2015-03-09 2019-04-24 Bristol-Myers Squibb Company Lactams as inhibitors of rock
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
UY37073A (es) 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen
US10562887B2 (en) 2016-05-27 2020-02-18 Bristol-Myers Squibb Company Triazolones and tetrazolones as inhibitors of ROCK
JP7113810B2 (ja) 2016-07-07 2022-08-05 ブリストル－マイヤーズ スクイブ カンパニー Ｒｏｃｋ阻害剤としてのスピロラクタム
JP6903731B2 (ja) * 2016-07-07 2021-07-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力で選択的なｒｏｃｋ阻害剤としてのラクタム、環状尿素、およびカルバメート、およびトリアゾロン誘導体
JP7155102B2 (ja) 2016-07-07 2022-10-18 ブリストル－マイヤーズ スクイブ カンパニー Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素
ES2829400T3 (es) 2016-11-30 2021-05-31 Bristol Myers Squibb Co Inhibidores tricíclicos de Rho cinasa
EP3652164B1 (en) 2017-07-12 2023-06-21 Bristol-Myers Squibb Company Phenylacetamides as inhibitors of rock
TW201908293A (zh) 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
ES2894128T3 (es) 2017-07-12 2022-02-11 Bristol Myers Squibb Co Inhibidores aminoheterocíclicos de cinco miembros y aminoheterocíclicos bicíclicos de 5,6 o 6,6 miembros de ROCK para el tratamiento de la insuficiencia cardíaca
US12060341B2 (en) 2017-07-12 2024-08-13 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as ROCK inhibitors
WO2019014304A1 (en) 2017-07-12 2019-01-17 Bristol-Myers Squibb Company SPIROHEPTANYL HYDANTOIDS AS ROCK INHIBITORS
EP3704121B1 (en) * 2017-11-03 2022-12-21 Bristol-Myers Squibb Company Diazaspiro rock inhibitors
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN112759550A (zh) * 2019-11-04 2021-05-07 上海科技大学 一种平滑受体拮抗剂
JP2021183586A (ja) * 2020-05-22 2021-12-02 武田薬品工業株式会社 複素環化合物
EP4431596A1 (en) 2021-11-11 2024-09-18 The Doshisha Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN119219603A (zh) * 2023-06-28 2024-12-31 科辉智药(深圳)新药研究中心有限公司 Sarm1酶活性抑制剂及其用途
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
CN120424050A (zh) * 2024-02-05 2025-08-05 科辉智药(深圳)新药研究中心有限公司 作为sarm1酶活性抑制剂的吡啶类化合物及其应用
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07183769A (ja) * 1993-12-22 1995-07-21 Fuji Electric Co Ltd ラッチ回路
JP2007519754A (ja) 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
WO2006048727A1 (en) * 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
CA2620818A1 (en) * 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
WO2009078992A1 (en) * 2007-12-17 2009-06-25 Amgen Inc. Linear tricyclic compounds as p38 kinase inhibitors
WO2009078991A1 (en) * 2007-12-17 2009-06-25 Peshina William F Oval cage coupler for filter cages
WO2010036316A1 (en) * 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
JP5769326B2 (ja) * 2010-10-19 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｈｏキナーゼ阻害薬
TW201443023A (zh) 2013-01-18 2014-11-16 必治妥美雅史谷比公司 作爲ｒｏｃｋ抑制劑之酞□酮及異喹啉酮
TW201444798A (zh) * 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
US9828345B2 (en) * 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
WO2015002926A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
TW201506024A (zh) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物
EP3027629B1 (en) 2013-07-31 2017-06-14 UDC Ireland Limited Luminescent diazabenzimidazole carbene metal complexes
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CA2935270A1 (en) * 2014-01-20 2015-07-23 F. Hoffmann-La Roche Ag N-phenyl-lactam derivatives capable of stimulating neurogenesis and their use in the treatment of neurological disorders
US9902702B2 (en) 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
JP6633618B2 (ja) 2014-08-21 2020-01-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体
CN107406426B (zh) 2015-01-09 2020-11-20 百时美施贵宝公司 作为rock抑制剂的环状脲类
EP3268360B1 (en) 2015-03-09 2019-04-24 Bristol-Myers Squibb Company Lactams as inhibitors of rock
UY37073A (es) 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen

Also Published As

Publication number Publication date
US20180000788A1 (en) 2018-01-04
JP2018501285A (ja) 2018-01-18
ES2815681T3 (es) 2021-03-30
US10123993B2 (en) 2018-11-13
CN107406426B (zh) 2020-11-20
CN107406426A (zh) 2017-11-28
WO2016112236A1 (en) 2016-07-14
EP3242873B1 (en) 2020-07-22
JP6779214B2 (ja) 2020-11-04
EP3242873A1 (en) 2017-11-15
TW201630899A (zh) 2016-09-01

Similar Documents

Publication Publication Date Title
AR103990A1 (es) Ureas cíclicas como inhibidoras de rock
AR094929A1 (es) Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
AR096788A1 (es) Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR129635A2 (es) Moduladores de tetrahidropiridopirazina de gpr6
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
AR106948A1 (es) Agonistas del receptor de apelina y método de uso
AR100059A1 (es) Compuestos útiles como inmunomoduladores
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR107973A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj
AR098414A1 (es) PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR093579A1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
AR100975A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR103232A1 (es) ANTAGONISTAS DE TGFbR

Legal Events

Date Code Title Description
FB Suspension of granting procedure